Table 1 Clinical characteristics of laparoscopic radical prostatectomy cases treated with or without neoadjuvant hormonal therapy groups * p < 0.05
From: Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
Variables | LRP* alone | LRP with NHT** |
|---|---|---|
No. of patients | 270 | 72 |
Mean age ± SD | 66.3 ± 6.1 | 67.7 ± 5.4 |
Mean serum PSA ± SD, ng/mL | 8.64 ± 5.2 | 9.81 ± 4.1 |
Biopsy Gleason grade, n(%) | ||
 ≤ 3 + 3 | 121 (44.8) | 30 (41.7) |
 3 + 4, 4 + 3 | 85 (31.5) | 25 (34.7) |
 ≥ 4 + 4 | 64 (23.7) | 17 (23.6) |
Clinical stage, n(%) | ||
 cT1c | 100 (37.0) | 27 (37.5) |
 cT2 | 170 (63.0) | 45 (62.5) |
D’Amico risk classification, n(%) | ||
 low | 76 (28.1) | 14 (19.4) |
 intermediate | 74 (27.4) | 24 (33.3) |
 high | 120 (44.4) | 34 (47.2) |
Pathological stage, n(%) | ||
 pT2 | 193 (71.5) | 62 (86.1) |
 pT3 | 77 (28.5) | *10 (13.9) |
Median operative time, min | 260 (121–572) | 276 (151–454) |
Median blood loss, ml | 600 (50–4500) | 600 (90–3928) |
Intraoperative complication | ||
 Rectum injury, n(%) | 4 (1.48) | 2 (2.78) |
 Blood transfusion, n(%) | 4 (1.48) | 2 (2.78) |
 Open surgery conversion, n(%) | 10 (3.70) | 3 (4.17) |
Positive surgical margin, n(%) | 114 (42.2) | *20 (27.8) |
Biochemical recurrence, n(%) | 48 (17.8) | 14 (19.4) |